Q1 Earnings Estimate for XENE Issued By Leerink Partnrs

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals' Q4 2025 earnings at ($1.23) EPS and FY2029 earnings at $2.05 EPS.

A number of other equities analysts also recently commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $57.38.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock traded down $1.23 during mid-day trading on Monday, reaching $35.79. 745,690 shares of the company were exchanged, compared to its average volume of 448,185. Xenon Pharmaceuticals has a fifty-two week low of $33.27 and a fifty-two week high of $47.80. The company has a market capitalization of $2.73 billion, a P/E ratio of -12.69 and a beta of 1.20. The business's 50 day simple moving average is $39.27 and its 200 day simple moving average is $40.33.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Large investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P increased its stake in shares of Xenon Pharmaceuticals by 7.1% in the third quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company's stock valued at $27,843,000 after purchasing an additional 46,964 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company's stock valued at $32,480,000 after acquiring an additional 300,000 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Xenon Pharmaceuticals by 4.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company's stock valued at $17,287,000 after acquiring an additional 17,953 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after acquiring an additional 905,129 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 13,903 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sherry Aulin sold 18,709 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,492 shares of company stock worth $2,334,969. 5.52% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.